A 6 Month Randomized, Open Label, Parallel Group, Safety Study Of Ciclesonide Nasal Aerosol (Zetonna) And Ciclesonide Nasal Spray (Omnaris) In Subjects 12 Years And Older With Perennial Allergic Rhinitis
Phase of Trial: Phase IV
Latest Information Update: 10 Oct 2015
At a glance
- Drugs Ciclesonide (Primary)
- Indications Perennial allergic rhinitis
- Focus Adverse reactions
- Sponsors Sunovion Pharmaceuticals
- 01 Jul 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 03 Jan 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 01 Sep 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.